Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noad231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Christina L Appin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Glioblastoma, Oligodendroglioma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
The TERT promoter mutation (TPM) is acquired in most IDH-wildtype glioblastomas (GBM) and IDH-mutant oligodendrogliomas (OD) enabling tumor cell immortality. Previous studies on TPM clonality show conflicting results. This study was performed to determine whether TPM is clonal on a tumor-wide scale.
Methods
We investigated TPM clonality in relation to presumed early events in 19 IDH-wildtype GBM and 10 IDH-mutant OD using 3-dimensional comprehensive tumor sampling. We performed Sanger sequencing on 264 tumor samples and deep amplicon sequencing on 187 tumor samples. We obtained tumor purity and copy number estimates from whole exome sequencing. TERT expression was assessed by RNA-seq and RNAscope.
Results
We detected TPM in 100% of tumor samples with quantifiable tumor purity (219 samples). Variant allele frequencies (VAF) of TPM correlate positively with chromosome 10 loss in GBM (R = 0.85), IDH1 mutation in OD (R = 0.87), and with tumor purity (R = 0.91 for GBM; R = 0.90 for OD). In comparison, oncogene amplification was tumor-wide for MDM4- and most EGFR-amplified cases but heterogeneous for MYCN and PDGFRA, and strikingly high in low-purity samples. TPM VAF was moderately correlated with TERT expression (R = 0.52 for GBM; R = 0.65 for OD). TERT expression was detected in a subset of cells, solely in TPM-positive samples, including samples equivocal for tumor.
Conclusions
On a tumor-wide scale, TPM is among the earliest events in glioma evolution. Intercellular heterogeneity of TERT expression, however, suggests dynamic regulation during tumor growth. TERT expression may be a tumor cell-specific biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, University of California, San Francisco, California, USA.
- Department of Neuropathology, University of Heidelberg, Institute of Pathology, Heidelberg, Germany.
ORCID-Profile: Christina L Appin, Radhika Mathur, Joseph F Costello
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- National Cancer Institute
- The Brain Tumor Funders Collaborative
Zitieren
APA
Appin, C. L., Hong, C., Suwala, A. K., Hilz, S., Mathur, R., Solomon, D. A., Smirnov, I. V., Stevers, N. O., Shai, A., Wang, A., Berger, M. S., Chang, S. M., Phillips, J. J., & Costello, J. F. (2024). Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad231
Vancouver
Appin CL, Hong C, Suwala AK, Hilz S, Mathur R, Solomon DA, et al. Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad231
BibTeX
@article{Appin2024,
author = {Appin, Christina L and Hong, Chibo and Suwala, Abigail K and Hilz, Stephanie and Mathur, Radhika and Solomon, David A and Smirnov, Ivan V and Stevers, Nicholas O and Shai, Anny and Wang, Albert and Berger, Mitchel S and Chang, Susan M and Phillips, Joanna J and Costello, Joseph F},
title = {Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noad231}
}
EUVIMED